In Vitro Hepatocyte Differentiation of Human Adipose-Derived Stem Cells Under Hypoxia and Photobiomodulation Irradiation.
Park IS.
Laboratory Study, published in Cell Reprogram (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Cell Reprogram (2025)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40720404
- DOI
- 10.1177/21524971251363134
- Citations
- 1
Abstract (original English)
Stem cells may be manipulated in vitro to induce hepatic differentiation. We investigated the effect of hypoxia and photobiomodulation therapy (PBMT) on the hepatogenic differentiation of human adipose-derived stem cells (hASCs). hASCs were exposed to different carbon dioxide concentrations with photobiomodulation (PBM) using low-level light. Cell survival and secretion of hepatocyte growth factor (HGF) of the hASCs were evaluated by immunostaining and Western blot analyses. Hepatic differentiation was assessed via immunocytochemical staining, fluorescence-activated cell sorting, and Western blot analysis for liver-specific genes and proteins, including albumin (ALB), cytokeratins 8/18, and alpha-fetoprotein (AFP). PBM therapy has been shown to enhance proliferation and cytokine secretion of a number of cells. The expression profiles of ALB, AFP, and cytokeratin 8/18 demonstrated that when HGF, hypoxia, or PBMT were treated individually, incomplete hepatocyte differentiation was achieved. In contrast, quantitative analysis of ALB, cytokeratins 8/18, and AFP showed that HGF was enhanced significantly by hypoxia+PBM treatment. The obtained cell populations contained progenitors that expressed both hepatic ALB and cytokeratin 8/18 markers, as well as AFP. These data suggest that PBMT and hypoxia are effective biostimulators of hASCs in hepatogenic differentiation, which enhances t
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.